Has anyone successfully used Dara and Dex as first-line treatment?

- Daratumumab (Dara) and dexamethasone (Dex) are commonly used in treating multiple myeloma. Daratumumab is a monoclonal antibody that targets the CD38 protein on myeloma cells, helping the immune system fight the cancer. It has been a breakthrough in read more

Has anyone successfully used Dara and Dex as first-line treatment?

- Daratumumab (Dara) and dexamethasone (Dex) are commonly used in treating multiple myeloma. Daratumumab is a monoclonal antibody that targets the CD38 protein on myeloma cells, helping the immune system fight the cancer. It has been a breakthrough in myeloma treatment and is often used in combination with other drugs.

Does blood type play into any treatment decisions?

- Blood type does not typically influence treatment decisions for multiple myeloma. Treatment choices are more often based on factors like genetic markers (e.g., deletion 17p), the type of myeloma (e.g., IgA, kappa), and the patient's overall health and response to previous treatments.

Diagnosed as IgA, kappa 20% BMB & high risk - deletion 17p

- Being diagnosed with IgA, kappa myeloma and having high-risk features like deletion 17p can influence treatment decisions. High-risk genetic markers may lead doctors to choose more aggressive or combination therapies to manage the disease effectively.

 This AI-generated response comes from MyMyelomaTeam and other selected sources. It is not a substitute for medical advice. Always ask your doctor about specific health concerns.

New Treatment Options for Relapsed or Refractory Myeloma | MyMyelomaTeam

Myeloma Treatments: Risks and Benefits | MyMyelomaTeam